Radioembolization With Holmium-166 Polylactic Acid Microspheres: Distribution of Residual Activity in the Delivery Set and Outflow Dynamics During Planning and Treatment Procedures
暂无分享,去创建一个
[1] P. Seifert,et al. Transarterial Radioembolization with Yttrium-90 Glass Microspheres: Distribution of Residual Activity and Flow Dynamics during Administration. , 2020, Journal of vascular and interventional radiology : JVIR.
[2] P. Seifert,et al. Ex Vivo Evaluation of Residual Activity and Infusion Dynamics in a Commercially Available Yttrium-90 Resin Microsphere Administration System. , 2019, Journal of vascular and interventional radiology : JVIR.
[3] Casper Beijst,et al. The superior predictive value of 166Ho-scout compared with 99mTc-macroaggregated albumin prior to 166Ho-microspheres radioembolization in patients with liver metastases , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[4] J. Nijsen,et al. The various therapeutic applications of the medical isotope holmium-166: a narrative review , 2019, EJNMMI Radiopharmacy and Chemistry.
[5] A. Braat,et al. Holmium-166 Microsphere Radioembolization of Hepatic Malignancies. , 2019, Seminars in nuclear medicine.
[6] G. Krijger,et al. Blood and urine analyses after radioembolization of liver malignancies with [166Ho]Ho-acetylacetonate-poly(l-lactic acid) microspheres. , 2019, Nuclear medicine and biology.
[7] M. A. van den Bosch,et al. Efficacy of Radioembolization with 166Ho-Microspheres in Salvage Patients with Liver Metastases: A Phase 2 Study , 2017, The Journal of Nuclear Medicine.
[8] Marnix G. E. H. Lam,et al. Safety analysis of holmium-166 microsphere scout dose imaging during radioembolisation work-up: A cohort study , 2017, European Radiology.
[9] H. Schild,et al. Evaluation of the delivered activity of yttrium-90 resin microspheres using sterile water and 5 % glucose during administration , 2015, EJNMMI Research.
[10] Marnix G E H Lam,et al. Safety of a Scout Dose Preceding Hepatic Radioembolization with 166Ho Microspheres , 2015, The Journal of Nuclear Medicine.
[11] T. Chua,et al. Transarterial chemoembolisation and radioembolisation for the treatment of primary liver cancer and secondary liver cancer: A review of the literature , 2014, Journal of medical imaging and radiation oncology.
[12] M. Viergever,et al. 99mTc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with 166Ho-microspheres , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[13] D. Eschelman,et al. Early arterial stasis during resin-based yttrium-90 radioembolization: incidence and preliminary outcomes. , 2014, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[14] M. A. van den Bosch,et al. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. , 2012, The Lancet. Oncology.
[15] M. A. van den Bosch,et al. Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial , 2010, Journal of experimental & clinical cancer research : CR.
[16] M. A. van den Bosch,et al. Holmium-166 poly(L-lactic acid) microsphere radioembolisation of the liver: technical aspects studied in a large animal model , 2009, European Radiology.
[17] J. Seppenwoolde,et al. Clinical effects of transcatheter hepatic arterial embolization with holmium-166 poly(l-lactic acid) microspheres in healthy pigs , 2008, European Journal of Nuclear Medicine and Molecular Imaging.